Back

When AI Meets the FDA: An Evaluation of Large Language Models Performance in Regulatory and Clinical Trial Data Extraction, Synthesis, and Analysis

2025-12-27 health policy Title + abstract only
View on medRxiv
Show abstract

IntroductionClinical and population decision-making relies on the systematic evaluation of extensive regulatory evidence. The FDA drug reviews provide detailed information on clinical trial design, enrollment criteria, sample size, randomization, comparators, endpoints, and indications. However, extracting these data is resource-intensive and time-consuming. Generative Artificial Intelligence large language models (LLMs) may accelerate the extraction and synthesis of such information. This study...

Predicted journal destinations